Nanoparticle version of coronavirus protein may be the key to a COVID-19 vaccine
Researchers at the University at Buffalo (NY, USA) have published an article in Advanced Materials discussing how the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein can be converted into particulate form to induce strongly neutralizing antibody responses against the novel coronavirus in animal studies. Johnathan Lovell (University at Buffalo), the lead author of the research, explained: “[It would be] appealing if a vaccine could induce high-levels of antibodies against the RBD…One way to achieve this goal is to use the RBD protein itself as an antigen, that is, the component of the vaccine that the immune response will be...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!